TCR2 Therapeutics (TCRR) Misses Q1 EPS by 26c

TCR2 Therapeutics (NASDAQ: TCRR) reported Q1 EPS of ($1.03), $0.26 worse than the analyst estimate of ($0.77).

For earnings history and earnings-related data on TCR2 Therapeutics (TCRR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c